Document And Entity Information
Document And Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Mar. 23, 2021 | Jun. 30, 2020 | |
Document Information [Line Items] | |||
Entity Registrant Name | BioCardia, Inc. | ||
Entity Central Index Key | 0000925741 | ||
Trading Symbol | bcda | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Emerging Growth Company | false | ||
Entity Small Business | true | ||
Entity Interactive Data Current | Yes | ||
Entity Common Stock, Shares Outstanding (in shares) | 16,339,061 | ||
Entity Public Float | $ 20.6 | ||
Entity Shell Company | false | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2020 | ||
Document Fiscal Year Focus | 2020 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false | ||
Title of 12(b) Security | Common Stock, par value $0.001 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 21,407 | $ 5,585 |
Accounts receivable, net of allowance for doubtful accounts of $16 and $2 at December 31, 2020 and 2019, respectively | 232 | 147 |
Inventory | 4 | |
Prepaid expenses and other current assets | 401 | 642 |
Other receivable due from related party | 618 | |
Total current assets | 22,658 | 6,378 |
Property and equipment, net | 145 | 181 |
Operating lease right-of-use asset, net | 567 | 1,065 |
Other assets | 54 | 54 |
Total assets | 23,424 | 7,678 |
Current liabilities: | ||
Accounts payable | 746 | 914 |
Accrued expenses and other current liabilities | 2,205 | 2,561 |
Deferred revenue | 683 | |
Operating lease liability - current | 614 | 528 |
Total current liabilities | 4,248 | 4,003 |
Operating lease liability - noncurrent | 614 | |
Deferred revenue | 691 | |
Total liabilities | 4,248 | 5,308 |
Commitments and contingencies (Note 15) | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value, 25,000,000 shares authorized as of December 31, 2020 and 2019, respectively; no shares issued and outstanding as of December 31, 2020 and 2019 | ||
Common stock, $0.001 par value, 100,000,000 shares authorized as of December 31, 2020 and 2019, respectively; 16,297,381 and 6,825,183 shares issued and outstanding as of December 31, 2020 and 2019, respectively | 16 | 7 |
Additional paid-in capital | 135,234 | 103,433 |
Accumulated deficit | (116,074) | (101,070) |
Total stockholders’ equity | 19,176 | 2,370 |
Total liabilities and stockholders’ equity | $ 23,424 | $ 7,678 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - USD ($) | Dec. 31, 2020 | Dec. 31, 2019 |
Allowance for doubtful accounts | $ 16,000 | $ 2,000 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 25,000,000 | 25,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 16,297,381 | 6,825,183 |
Common stock, shares outstanding (in shares) | 16,297,381 | 6,825,183 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Revenue: | ||
Total revenue | $ 145,000 | $ 710,000 |
Costs and expenses: | ||
Cost of goods sold | 4,000 | 358,000 |
Research and development | 9,809,000 | 8,562,000 |
Selling, general and administrative | 5,861,000 | 6,003,000 |
Total costs and expenses | 15,674,000 | 14,923,000 |
Operating loss | (15,529,000) | (14,213,000) |
Other income (expense): | ||
Interest income | 21,000 | 87,000 |
Gain on change in fair value of redemption feature embedded in convertible notes | 52,000 | |
Interest expense | (3,000) | (112,000) |
Other expense | (2,000) | (2,000) |
Total other income (expense) | 525,000 | (496,000) |
Net loss | $ (15,004,000) | $ (14,709,000) |
Net loss per share, basic and diluted (in dollars per share) | $ (1.48) | $ (2.61) |
Weighted-average shares used in computing net loss per share, basic and diluted (in shares) | 10,118,682 | 5,644,328 |
Convertible Notes Payable [Member] | ||
Other income (expense): | ||
Gain (loss) on extinguishment of debt | $ (521,000) | |
Paycheck Protection Program CARES Act [Member] | ||
Other income (expense): | ||
Gain (loss) on extinguishment of debt | 509,000 | |
Product [Member] | ||
Revenue: | ||
Total revenue | 13,000 | 182,000 |
Collaboration Agreement [Member] | ||
Revenue: | ||
Total revenue | $ 132,000 | $ 528,000 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands | Restricted Stock Units (RSUs) [Member]Management [Member]Common Stock [Member] | Restricted Stock Units (RSUs) [Member]Management [Member]Additional Paid-in Capital [Member] | Restricted Stock Units (RSUs) [Member]Management [Member]Retained Earnings [Member] | Restricted Stock Units (RSUs) [Member]Management [Member] | Restricted Stock Units (RSUs) [Member]Board of Directors [Member]Common Stock [Member] | Restricted Stock Units (RSUs) [Member]Board of Directors [Member]Additional Paid-in Capital [Member] | Restricted Stock Units (RSUs) [Member]Board of Directors [Member]Retained Earnings [Member] | Restricted Stock Units (RSUs) [Member]Board of Directors [Member] | Restricted Stock Units (RSUs) [Member]Common Stock [Member] | Restricted Stock Units (RSUs) [Member]Additional Paid-in Capital [Member] | Restricted Stock Units (RSUs) [Member]Retained Earnings [Member] | Restricted Stock Units (RSUs) [Member] | Public Offering [Member]Common Stock [Member] | Public Offering [Member]Additional Paid-in Capital [Member] | Public Offering [Member]Retained Earnings [Member] | Public Offering [Member] | The $8.5 Million Registered Direct Offering [Member]Common Stock [Member] | The $8.5 Million Registered Direct Offering [Member]Additional Paid-in Capital [Member] | The $8.5 Million Registered Direct Offering [Member]Retained Earnings [Member] | The $8.5 Million Registered Direct Offering [Member] | The $10.5 Million Registered Direct Offering [Member]Common Stock [Member] | The $10.5 Million Registered Direct Offering [Member]Additional Paid-in Capital [Member] | The $10.5 Million Registered Direct Offering [Member]Retained Earnings [Member] | The $10.5 Million Registered Direct Offering [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2018 | 4,845,697 | |||||||||||||||||||||||||||
Balance at Dec. 31, 2018 | $ 5 | $ 90,148 | $ (86,361) | $ 3,792 | ||||||||||||||||||||||||
Reverse stock split fractional share true up (in shares) | (494) | |||||||||||||||||||||||||||
Restricted stock units vested and issued (in shares) | 27,426 | |||||||||||||||||||||||||||
Sale of common stock (in shares) | 1,741,667 | |||||||||||||||||||||||||||
Common stock issued | $ 2 | 9,194 | 9,196 | |||||||||||||||||||||||||
Issuance of stock and warrants from conversion of convertible notes (in shares) | 210,887 | |||||||||||||||||||||||||||
Issuance of stock and warrants from conversion of convertible notes | 1,204 | 1,204 | ||||||||||||||||||||||||||
Issuance of restricted stock units in lieu of 2018 cash bonus | 165 | 165 | ||||||||||||||||||||||||||
Share-based compensation | 2,722 | 2,722 | ||||||||||||||||||||||||||
Net loss | (14,709) | (14,709) | ||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2019 | 6,825,183 | |||||||||||||||||||||||||||
Balance at Dec. 31, 2019 | $ 7 | 103,433 | (101,070) | 2,370 | ||||||||||||||||||||||||
Restricted stock units vested and issued (in shares) | 71,624 | 39,807 | 26,172 | |||||||||||||||||||||||||
Sale of common stock (in shares) | 5,476,190 | 1,789,474 | 2,038,836 | |||||||||||||||||||||||||
Common stock issued | $ 5 | $ 10,268 | $ 10,273 | $ 2 | $ 7,825 | $ 7,827 | $ 2 | $ 9,763 | $ 9,765 | |||||||||||||||||||
Share-based compensation | 2,952 | 2,952 | ||||||||||||||||||||||||||
Net loss | (15,004) | (15,004) | ||||||||||||||||||||||||||
Restricted stock units vested and issued | ||||||||||||||||||||||||||||
Restricted stock units issued | $ 232 | $ 232 | $ 613 | $ 613 | ||||||||||||||||||||||||
Common stock grants to former directors to settle board compensation obligations (in shares) | 29,625 | |||||||||||||||||||||||||||
Common stock grants to former directors to settle board compensation obligations | 148 | 148 | ||||||||||||||||||||||||||
Exercise of common stock warrants (in shares) | 470 | |||||||||||||||||||||||||||
Exercise of common stock warrants | ||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2020 | 16,297,381 | |||||||||||||||||||||||||||
Balance at Dec. 31, 2020 | $ 16 | $ 135,234 | $ (116,074) | $ 19,176 |
Consolidated Statements of St_2
Consolidated Statements of Stockholders' Equity (Parentheticals) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Public Offering [Member] | ||
Issuance costs | $ 1,227 | |
The $8.5 Million Registered Direct Offering [Member] | ||
Issuance costs | 673 | |
The $10.5 Million Registered Direct Offering [Member] | ||
Issuance costs | $ 735 | |
Issuance costs | $ 1,259 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Operating activities: | ||
Net loss | $ (15,004,000) | $ (14,709,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 68,000 | 111,000 |
Reduction in the carrying amount of right-of-use assets | 498,000 | 440,000 |
Non-cash interest expense on convertible stockholder notes | 3,000 | 112,000 |
Gain (loss) on extinguishment of debt | (52,000) | |
Share-based compensation | 2,952,000 | 2,722,000 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (85,000) | 127,000 |
Inventory | 4,000 | 137,000 |
Prepaid expenses and other current assets | 241,000 | (198,000) |
Other receivable due from related party | (618,000) | |
Accounts payable | (168,000) | 171,000 |
Accrued liabilities excluding accrued interest on convertible note | 797,000 | 922,000 |
Deferred revenue | (8,000) | 691,000 |
Operating lease liability - current | 86,000 | 88,000 |
Operating lease liability - noncurrent | (614,000) | (528,000) |
Net cash used in operating activities | (12,357,000) | (9,445,000) |
Investing activities: | ||
Purchase of property and equipment | (32,000) | (146,000) |
Net cash used in investing activities | (32,000) | (146,000) |
Financing activities: | ||
Proceeds from sale of common stock and warrants | 10,452,000 | |
Issuance costs from sales of common stock and warrants | (1,259,000) | |
Issuance costs from sales of common stock | (2,635,000) | |
Proceeds from Paycheck Protection Program note payable | 506,000 | |
Tax withholding payments on settlement of restricted stock unit awards | (160,000) | |
Proceeds from convertible notes payable | 625,000 | |
Net cash provided by financing activities | 28,211,000 | 9,818,000 |
Net change in cash and cash equivalents | 15,822,000 | 227,000 |
Cash and cash equivalents at beginning of year | 5,585,000 | 5,358,000 |
Cash and cash equivalents at end of year | 21,407,000 | 5,585,000 |
Supplemental disclosure for noncash investing and financing activities: | ||
Restricted stock units issued to settle management bonus obligations | 391,000 | |
Common stock grants to former directors to settle board compensation obligations | 148,000 | |
Restricted stock units issued to settle board compensation obligations | 613,000 | |
Conversion of interest payable to stock and warrants | 633,000 | |
Issuance of restricted stock units in lieu of 2018 cash bonus | 165,000 | |
Right-of-use asset obtained in exchange for lease obligation | 1,505,000 | |
Cashless exercise of warrant | ||
Public Offering [Member] | ||
Financing activities: | ||
Proceeds from sale of common stock | 11,500,000 | |
The $8.5 Million Registered Direct Offering [Member] | ||
Financing activities: | ||
Proceeds from sale of common stock | 8,500,000 | |
The $10.5 Million Registered Direct Offering [Member] | ||
Financing activities: | ||
Proceeds from sale of common stock | 10,500,000 | |
Paycheck Protection Program CARES Act [Member] | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Gain (loss) on extinguishment of debt | (509,000) | |
Convertible Notes Payable [Member] | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Gain (loss) on extinguishment of debt | $ 521,000 |
Note 1 - Summary of Business
Note 1 - Summary of Business | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | ( 1 Summary of Business (a) Description of Business BioCardia, Inc. (BioCardia or the Company), is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular and respiratory diseases with significant unmet medical needs. The Company's lead therapeutic candidate is the CardiAMP® Cell Therapy System, which provides an autologous bone marrow derived cell therapy using a patient's own cells for treatment in two second 1 BioCardia also has three 1 2 3 |
Note 2 - Significant Accounting
Note 2 - Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | ( 2 Significant Accounting Policies (a) Basis of Presentation and Consolidation These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All material intercompany accounts and transactions have been eliminated during the consolidation process. (b) Liquidity The Company has incurred net losses and negative cash flows from operations since its inception and had an accumulated deficit of $116.1 December 31, 2020. Cash and cash equivalents totaled $21.4 December 31, 2021, 12 10 (c) Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires Company management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates and assumptions include the useful lives of property and equipment, right-of-use assets and related liabilities, allowances for doubtful accounts and sales returns; inventory valuation, derivative instruments, clinical accruals, share-based compensation and the assumptions used for revenue recognition. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates. (d) Cash Equivalents The Company classifies all highly liquid investments with an original maturity date of 90 (e) Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains its cash at reputable U.S. financial institutions, which at times, exceed federally insured limits of $250,000 December 31, 2020, one not not (f) Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and do not not $16,000 $2,000 December 31, 2020 2019, (g) Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using the average-cost method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company analyzes its inventory levels quarterly and writes down inventory that has become obsolete or has a cost basis in excess of its expected net realizable value or inventory quantities in excess of expected requirements. Excess requirements are determined based on comparison of existing inventories to forecasted sales, with consideration given to inventory shelf life. Expired inventory is disposed of and the related costs are recognized in cost of goods sold. (h) Property and Equipment, Net Property and equipment, net, are carried at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets, as described in the table below. Maintenance and repairs are expensed as incurred. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is reflected in the accompanying consolidated statements of operations. Asset Estimated useful lives (in years) Computer equipment and software 3 Laboratory and manufacturing equipment 3 Furniture and fixtures 3 Leasehold improvements 5 years or lease term, if shorter (i) Right-of-Use Assets Operating lease right-of-use asset and liabilities 12 The Company's lease liabilities are recognized at the applicable lease commencement date based on the present value of the lease payments required to be paid over the lease term. Variable lease payments are expensed as incurred and are not The Company's ROU assets are also recognized at the applicable lease commencement date. The ROU asset equals the carrying amount of the related lease liability, adjusted for any lease payments made prior to lease commencement and lease incentives provided by the lessor, if any. The Company reduces a ROU asset, and the periodic reduction is the difference between the straight-line total lease cost for the period (including reduction of initial direct costs) and the periodic accretion of the lease liability using the effective interest method. The Company's lease terms may The Company's lease contracts often include lease and non-lease components. The Company has elected the practical expedient offered by the standard to not The Company has elected not twelve (j) Long-lived Assets Impairment assessment of long-lived assets may not December 31, 2020, no (k) Clinical Trial Accruals As part of the process of preparing its consolidated financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiation and may not not may may (l) Derivatives The Company accounts for its derivative instruments as either assets or liabilities on the consolidated balance sheets and measures them at fair value. Derivatives are adjusted to fair value through other (expense) income, net, in the consolidated statements of operations. Derivatives settled in cash or with another financial instrument are reflected in the consolidated statements of cash flows in the same section as the related items. (m) Revenue Recognition Net product revenue Collaboration agreement revenue In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may not The Company applies judgment in determining whether a combined performance obligation is satisfied at a point in time or over time, and, if over time, concluding upon the appropriate method of measuring progress to be applied for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, as estimates related to the measure of progress change, related revenue recognition is adjusted accordingly. Changes in the Company's estimated measure of progress are accounted for prospectively as a change in accounting estimate. The Company recognizes collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. The Company will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company's consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve may not one December 31, 2020, $683,000, $183,000 $500,000, July 2021. Multiple contracts with the same customer - two one one Contract costs - one not Contract modifications - one not not not (n) Shipping Costs Costs incurred for the shipping of products to customers totaled approximately $0 $6,000 December 31, 2020 2019, (o) Product Warranties The Company provides a standard warranty of serviceability on all its products for the duration of the product's shelf life, which is two not December 31, 2020 2019. (p) Research and Development The Company's research and development costs are expensed as incurred. Research and development expense include the costs of basic research activities as well as other research, engineering, and technical effort required to develop new products or services or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and support costs for collaborative partnering programs wherein the Company provides biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. The Company's research and development costs consist primarily of: • Salaries, benefits and other personnel-related expenses, including share-based compensation; • Fees paid for services provided by clinical research organizations, research institutions, consultants and other outside service providers; • Costs to acquire and manufacture materials used in research and development activities and clinical trials; • Laboratory consumables and supplies; • Facility-related expenses allocated to research and development activities; • Fees to collaborators to license technology; and • Depreciation expense for equipment used for research and development and clinical purposes. (q) Cost of Goods Sold Cost of goods sold includes the costs of raw materials and components, manufacturing personnel and facility costs and other indirect and overhead costs associated with manufacturing the commercial enabling and delivery products, which generate net product revenue. (r) Share-Based Compensation The Company measures and recognizes share-based compensation expense for equity awards to employees, directors and consultants based on fair value at the grant date. The Company uses the Black-Scholes-Merton (BSM) option pricing model to calculate fair value of its stock option grants. The compensation cost for restricted stock awards is based on the closing price of the Company's common stock on the date of grant. Share-based compensation expense recognized in the consolidated statements of operations is based on the period the services are performed and recognized as compensation expense on a straight-line basis over the requisite service period. The Company accounts for forfeitures as they occur. Measurement of nonemployee awards - The measurement of equity-classified nonemployee awards is fixed at the grant date, and the Company may 505 50 The BSM option pricing model requires the input of subjective assumptions, including the risk-free interest rate, the expected volatility in the value of the Company's common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management's judgment. If factors change and different assumptions are used, the share-based compensation expense could be materially different in the future. These assumptions are estimated as follows: Risk-free Interest Rate The risk-free interest rate assumption is based on the zero Expected Volatility The Company has limited historical data of its own to utilize in determining expected volatility. As such the Company based the volatility assumption on a combined weighted average of the Company's own historical data and that of a selected peer group. The peer group was developed based on companies in the biotechnology and medical device industries whose shares are publicly traded. Expected Term The expected term represents the period of time that options are expected to be outstanding. As the Company does not (s) Income Taxes The Company accounts for income taxes based on the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets, liabilities, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not not In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, forecasts of future taxable income, and ongoing tax planning. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not The Company recognizes and measures benefits for uncertain tax positions using a two first not not second 50% No (t) Fair Value of Financial Instruments The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the consolidated financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Where observable prices or inputs are not The Company's financial assets and liabilities consist principally of cash and cash equivalents, accounts receivable, and accounts payable. The fair value of the Company's cash equivalents is determined based on quoted prices in active markets for identical assets. Cash in the Company's operating bank accounts represents the difference between cash in the money market accounts and total cash and cash equivalents reported on the consolidated balance sheets. The recorded values of the Company's accounts receivable and accounts payable approximate their current fair values due to the relatively short-term nature of these accounts. (u) Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Common stock equivalents are comprised of restricted stock units, warrants to purchase common stock and options outstanding under the stock option plans. For all periods presented, there is no (v) Recent Accounting Pronouncements In October 2020, 2020 10— Codification Improvements. December 15, 2020. not not 2020 10. 50 not In March 2020, accelerated filer large accelerated filer No. 34 88365 12b 2 1934 $700 $100 $75 not In December 2019, 2019 12 (Topic 740 December 15, 2020, not In June 2016, No. 2016 13, (Topic 326 December 15, 2022, not Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did not not |
Note 3 - Fair Value Measurement
Note 3 - Fair Value Measurements | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | ( 3 Fair Value Measurements The fair value of financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company follows a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into the following three Level 1 Level 2 not Level 3 no The following table sets forth the fair value of the financial assets measured on a recurring basis as of December 31, 2020 2019 As of December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 20,662 $ - $ - $ 20,662 Cash in checking accounts - - - 745 Total cash and cash equivalents $ 20,662 $ — $ — $ 21,407 As of December 31, 2019 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 4,637 $ - $ - $ 4,637 Cash in checking accounts - - - 948 Total cash and cash equivalents $ 4,637 $ — $ — $ 5,585 |
Note 4 - Inventories
Note 4 - Inventories | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | ( 4 Inventories Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consist of the following (in thousands): December 31, 2020 2019 Raw materials $ — $ — Work in process — — Finished goods — 4 Total $ — $ 4 Write downs for excess or expired inventory are based on management's estimates of forecasted usage of inventories and are included in cost of goods sold. A significant change in the timing or level of demand for certain products as compared to forecasted amounts may $2,000 $36,000 December 31, 2020, 2019, |
Note 5 - Property and Equipment
Note 5 - Property and Equipment, Net | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | ( 5 Property and Equipment, Net Property and equipment, net consist of the following (in thousands): December 31, 2020 2019 Computer equipment and software $ 159 $ 132 Laboratory and manufacturing equipment 550 550 Furniture and fixtures 59 55 Leasehold improvements 332 332 Construction in progress 70 69 Property and equipment, gross 1,170 1,138 Less accumulated depreciation (1,025 ) (957 ) Property and equipment, net $ 145 $ 181 Depreciation expense totaled approximately $68,000 $111,000 December 31, 2020 2019, |
Note 6 - Operating Lease Right-
Note 6 - Operating Lease Right-of-use Asset, Net | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | ( 6 Operating Lease Right-of-Use Assets, Net The Company determines if an arrangement is a lease at inception by assessing whether it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company's operating lease, which expires in December 2021, not ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company's lease does not not no The components of lease expense for the year ended December 31, 2020 2019, December 31, 2020 2019 Straight-line rent expense recognized for operating lease $ 601 $ 601 Variable rent expense recognized for operating lease 395 264 Total rent expense $ 996 $ 865 Weighted average remaining lease term (in years) 1.0 2.0 Weighted average discount rate 12.05 % 12.05 % Supplemental cash flow information related to the operating lease was as follows (in thousands): December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities $ 630 $ 612 Cash lease expense (imputed interest expense component of net income) $ 103 $ 161 Future minimum lease payments under the operating lease as of December 31, 2020 For the years ending December 31, 2021 $ 649 2022 — 2023 — Thereafter — Total undiscounted lease payments 649 Less imputed interest 35 Total operating lease liabilities $ 614 |
Note 7 - Collaborative Agreemen
Note 7 - Collaborative Agreements | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Collaborative Arrangement Disclosure [Text Block] | ( 7 Collaborative Agreements The Company has entered into various collaborations related to clinical development. These agreements allow partners to utilize the Company's enabling biotherapeutic delivery systems, including training and support during clinical and preclinical delivery of biotherapeutics. Under the terms of these agreements, the Company typically receives a use fee and payments for the systems and services provided. The Company gains access to certain data generated by its partners for use in its own product development efforts and also receives nonexclusive patent rights to any partner discovered BioCardia technology improvement inventions. Revenue from collaborative agreements is recognized in the Consolidated Statements of Operations in the line “Collaboration agreement revenue.” |
Note 8 - Accrued Expenses and O
Note 8 - Accrued Expenses and Other Current Liabilities | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Accrued Liabilities and Other Current Liabilities Disclosure [Text Block] | ( 8 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): December 31, 2020 2019 Accrued expenses $ 87 $ 10 Accrued salaries and employee benefits 961 652 Accrued director compensation — 648 Accrued clinical trial costs 452 519 Grant liability 615 630 Customer deposits 90 102 Total $ 2,205 $ 2,561 |
Note 9 - Note Payable Under Pay
Note 9 - Note Payable Under Paycheck Protection Program | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | ( 9 Note payable under Paycheck Protection Program On May 1, 2020, $506,413 May 1, 2020. In accordance with the requirements of the CARES Act, the Borrower used the proceeds from the Note in accordance with the requirements of the PPP to cover certain qualified expenses, including payroll costs, rent and utility costs. Interest accrued on the Note at the rate of 1.00% may eight June 5, 2020, eight twenty-four Subject to any forgiveness under the PPP, the Note would have matured two first six October 7, 2020, $506,000 $3,000 November 2, 2020. $509,000 December 31, 2020. |
Note 10 - Stockholders' Equity
Note 10 - Stockholders' Equity | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | ( 10 Stockholders Equity $10.5 December 15, 2020, December 15 2,038,836 December 15 $0.001 $5.15 December 15 $10.5 7.0% December 15 December 18, 2020, December 15 not $9.8 December 15 3, October 9, 2020, October 20, 2020, December 15, 2020. $8.5 December 14, 2020, December 14 1,789,474 December 14 $0.001 $4.75 December 14 $8.5 7.0% December 14 not $40,000. December 16, 2020, December 14 not $7.8 December 14 3, October 9, 2020, October 20, 2020, December 14, 2020. 2020 1 May 2020, 1 1 June 17, 2020, 1, 4,762,000 $0.001 $2.10 45 714,190 June 18, 2020. June 19, 2020. $10.3 On June 8, 2020, 29,625 two $148,000. Public Offering on Form S- 1 April 2019, 1 1 August 2, 2019, 1, 1,666,667 one $0.001 one $6.00 $6.30 five 11,958 $6.60 45 250,000 250,000 August 6, 2019. $8.8 September 4, 2019, 75,000 250,000 $420,000, $32,000. Up List to Nasdaq August 2, 2019, Convertible Note Financing July 5, 2019, $625,000 14.0% six January 5, 2020. 50% $52,000. $521,000. December 31, 2019 $112,000 $104,000 Upon the closing of the Company's public offering of units on August 6, 2019 $633,000, 210,887 one one $3.00 one $8.00 Reverse Stock Split June 6, 2019, 1 9 Sales of Unregistered Common Stock and Warrants December 24, 2018, 592,592 $6.75 one 296,296 $3.8 $200,000 six December 31, 2020, no $6.75 December 24, 2023. Warrants Number of Weighted Common Stock Average Warrants Exercise Price Balance, December 31, 2019 2,435,807 $ 6.36 Warrants for common stock sold — — Warrants for common stock exercised (11,083 ) 6.60 Balance, December 31, 2020 2,424,724 $ 6.36 On December 24, 2020, 11,083 470 |
Note 11 - Share-based Compensat
Note 11 - Share-based Compensation | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | ( 11 Share-Based Compensation BioCardia Lifesciences adopted, and the BioCardia Lifesciences shareholders approved, the 2002 2002 “2002 2002 not not 2002 2016, 2016 “2016 2016 2016 2002 2016 four ten no 2016 2016 2016 first 4% 268,997 1,000,000 January 1, 2021). December 31, 2020, 160,020 2016 The Company recognizes in the consolidated statements of operations the grant-date fair value of stock options and other equity-based compensation. Share-based compensation expense for the years ended December 31, 2020 2019 Years ended December 31, 2020 2019 Cost of goods sold $ - $ 191 Research and development 1,369 1,115 Selling, general and administrative 1,583 1,416 Total stock-based compensation $ 2,952 $ 2,722 On January 29, 2020 ( $5.32 No 515,036 $10.05 $97.21, The repricing on January 29, 2020 $569,000, $412,000 $157,000 three The following table summarizes activity under the Company's stock option plans, including the 2002 2016 Options outstanding Number of shares Weighted average exercise price Weighted average remaining contractual term (years) Aggregate intrinsic value (in thousands) Balance, December 31, 2019 821,464 $ 18.99 7.6 $ - Stock options granted 342,232 3.10 Stock options exercised — — Stock options cancelled (49,390 ) 12.79 Balance, December 31, 2020 1,114,306 $ 5.89 7.5 $ 177.1 Options exercisable December 31, 2020 615,470 $ 7.51 6.3 $ 15.6 Options vested and expected to vest 1,114,306 $ 5.89 7.5 $ 177.1 The aggregate intrinsic value represents the difference between the total pre-tax value (i.e., the difference between the Company's stock price and the exercise price) of stock options outstanding as of December 31, 2020, $3.46 The total intrinsic value of options exercised during the years ended December 31, 2020 2019 zero December 31, 2020 2019 $1.73 $3.87 Employee, Director and Non-employee Share-Based Compensation During the years ended December 31, 2020 2019, 342,232 254,785 Years ended December 31, 2020 2019 Risk-free interest rate 0.4 - 1.6% 1.40 - 2.14% Volatility 107 - 112% 74 - 94% Dividend yield None None Expected term (in years) 6.25 - 10.0 6.25 - 10.0 Unrecognized share-based compensation for employees, non-employee directors and non-employee options granted through December 31, 2020 $2.1 2.2 Share-Based Compensation (RSUs) During the years ended December 31, 2020 2019, 113,976 34,713 During the year ended December 31, 2020, 122,977 $613,000 April 2018 March 30, 2020. December 31, 2020, 69,321 $190,000 April 1, 2020 December 31, 2020. $92,500 $4 one two 2016 The following table summarizes the activity for RSUs during the year ended December 31, 2020: Weighted average grant date Number of fair values shares per share Balance, December 31, 2019 36,981 $ 10.56 RSUs granted 381,094 3.93 RSUs vested and settled (137,603 ) 5.48 RSUs forfeited (56,161 ) 3.75 Balance, December 31, 2020 224,311 $ 4.12 RSUs vested and settled are converted into the Company's common stock on a one one 224,311 December 31, 2020, 216,111 not 8,200 not December 31, 2020 $37,000 2.3 |
Note 12 - Concentrations
Note 12 - Concentrations | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | ( 12 Concentrations Most of the Company's customers are located in the United States. Two customers accounted for approximately 70% 16% 2020. 43% 25% 2019. 22%, 18% 11% December 31, 2020. 15% December 31, 2019. |
Note 13 - Net Loss Per Share
Note 13 - Net Loss Per Share | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | ( 13 Net Loss per Share The following table sets forth the computation of the basic and diluted net loss per share for the years ended December 31, 2020 2019 Years ended December 31, 2020 2019 Numerator: Net loss $ (15,004 ) $ (14,709 ) Denominator: Weighted average shares used to compute net loss per share, basic and diluted 10,118,682 5,644,328 Net loss per share, basic and diluted $ (1.48 ) $ (2.61 ) The following weighted-average outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: At December 31, 2020 2019 Stock options to purchase common stock 1,114,306 821,464 Unvested restricted stock units 8,200 36,981 Common stock warrants 2,424,724 2,435,808 Total 3,547,230 3,294,253 |
Note 14 - Income Taxes
Note 14 - Income Taxes | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | ( 14 Income Taxes The Company's provision for income taxes for the years ended December 31, 2020 2019 $0 The provision for income taxes differs from the amount which would result by applying the federal statutory income tax rate to pre-tax loss for the years ended December 31, 2020 2019. Years ended December 31, 2020 2019 Tax at federal statutory rate $ (3,151 ) $ (3,089 ) State, net of federal benefit (449 ) (414 ) Research and development credit (276 ) (225 ) Share-based compensation 649 446 PPP Note forgiveness (107 ) - Other 2 5 Change in valuation allowance 3,332 3,277 Total provision for income taxes $ — $ - Deferred income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss and tax credit carryforwards, net of any adjustment for unrecognized tax benefits. The components of the net deferred income tax assets as of December 31, 2020 2019 Years ended December 31, 2020 2019 Accrued compensation $ 225 $ 148 Inventory adjustments 335 297 Depreciation and amortization 90 98 Share-based compensation 686 744 Net operating loss and tax credit carryforwards 26,931 23,809 Other 173 11 Gross Deferred Tax Asset 28,440 25,107 Valuation Allowance (28,440 ) (25,107 ) Net deferred tax asset $ - $ - The Company has approximately $91.5 $62.7 December 31, 2020. 2022 2028 2020, 2019, 2018 no may may may one not 50% three Generally, utilization of the net operating loss carryforwards and credits may 382, 383, 1986, may not 382 383 As of December 31, 2020, $2.8 $2.1 2028. no The Company does not not not December 31, 2020 2019. December 31, 2020 $3.3 December 31, 2019 $3.2 No The aggregate changes in the balance of gross unrecognized tax benefits were as follows (in thousands): Years ended December 31, 2020 2019 Balance, beginning of year $ 1,046 $ 891 Additions based on tax positions related to the current year 189 155 Balance, end of year $ 1,235 $ 1,046 Recognition of approximately $895,000 $753,000 December 31, 2020 2019 2020 2019 On May 1, 2020, $506,413 2.5 eight The Consolidated Appropriations Act, 2021, 116 260, Dec. 27, 2020, not not The Company applied for and received a PPP loan for $506,413 2020. $3,000 November 2, 2020. The Company is subject to U.S. federal, California, Colorado, Florida and North Carolina income taxes. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company was incorporated in 2002 |
Note 15 - Contingencies and Unc
Note 15 - Contingencies and Uncertainties | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Contingencies Disclosure [Text Block] | ( 15 Contingencies and Uncertainties Contingencies may not Uncertainties December 31, 2020 not December 31, 2021 19, 19, Beginning March 17, 2020, April 6, 2020, December 31, 2020, may 19 As the outbreak continues to mutate and spread, it may third may may 19 may may Additionally, while the potential economic impact brought by, and the duration of, a coronavirus pandemic is difficult to assess or predict, the impact of the coronavirus on the global financial markets may 2020 10 not third |
Note 16 - Grant Funding
Note 16 - Grant Funding | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Grant Funding [Text Block] | ( 16 Grant Funding In June 2016, 1998 not $750,000 three June 2021. As of December 31, 2020, $750,000 $135,000 December 31, 2020. $615,000 December 31, 2020. |
Note 17 - Related Party Transac
Note 17 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | ( 17 Related Party Transactions Litigation Funding Agreement On April 9, 2020, No. 3:19 05645 Under the terms of the Funding Agreement, the Funder agreed to fund the legal fees and costs incurred by the Company in connection with the Litigation on and after March 1, 2020 50% three 30% Although the Company is required under the terms of the Funding Agreement to consult with the Funder regarding any settlement in connection with the Litigation and to allow Funder to participate in any real-time settlement negotiations, the Company has the sole and exclusive right to settle on whatever terms it deems acceptable. The Funding Agreement may ten may ten ten December 31, 2020 $618,000. On March 12, 2021, not OPKO BioCardia, Inc. and OPKO Health, Inc. (OPKO) previously entered into a consulting agreement dated August 19, 2016, 5% Pursuant to the terms of the Consulting Agreement, OPKO was to provide advisory services to the Company in support of strategic transactions, financings and other matters as agreed between the parties from time to time. Also, in August 2016, ten 46,553 4 $16.20 four one Effective August 29, 2019, no ten August 2019. $225,000 $167,000 December 31, 2019. Convertible Note Financing On July 5, 2019, $625,000 10 |
Note 18 - Employee Benefit Plan
Note 18 - Employee Benefit Plans | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Retirement Benefits [Text Block] | ( 18 Employee Benefit Plans The Company's U.S. employees are eligible to participate in a retirement and savings plan that qualifies under Section 401 may 75% not $26,000 $25,000 December 31, 2020 2019, |
Note 19 - Subsequent Events
Note 19 - Subsequent Events | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | ( 19 Subsequent Events On February 17, 2021, $500,000 one On March 29, 2021, $2 373,832 $5.35 $20 $2 In consideration for entering into the purchase agreement with Lincoln Park, the Company agreed to issue an aggregate of 75,000 50,000 $20 March 29, 2021, 80,000 5,000 $2 not The net proceeds under the purchase agreement to the Company will depend on the frequency and prices at which shares of common stock are sold to Lincoln Park. Actual sales of shares of common stock to Lincoln Park under the purchase agreement and the amount of such net proceeds will depend on a variety of factors, including market conditions, the trading price of the common stock and determination by the Company as to other available and appropriate sources of funding for the Company. The Company expects to use the proceeds from this agreement for general corporate purposes and working capital. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | (a) Basis of Presentation and Consolidation These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All material intercompany accounts and transactions have been eliminated during the consolidation process. |
Going Concern and Liquidity [Policy Text Block] | (b) Liquidity The Company has incurred net losses and negative cash flows from operations since its inception and had an accumulated deficit of $116.1 December 31, 2020. Cash and cash equivalents totaled $21.4 December 31, 2021, 12 10 |
Use of Estimates, Policy [Policy Text Block] | (c) Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires Company management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates and assumptions include the useful lives of property and equipment, right-of-use assets and related liabilities, allowances for doubtful accounts and sales returns; inventory valuation, derivative instruments, clinical accruals, share-based compensation and the assumptions used for revenue recognition. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates. |
Cash and Cash Equivalents, Policy [Policy Text Block] | (d) Cash Equivalents The Company classifies all highly liquid investments with an original maturity date of 90 |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | (e) Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains its cash at reputable U.S. financial institutions, which at times, exceed federally insured limits of $250,000 December 31, 2020, one not not |
Accounts Receivable [Policy Text Block] | (f) Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and do not not $16,000 $2,000 December 31, 2020 2019, |
Inventory, Policy [Policy Text Block] | (g) Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using the average-cost method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company analyzes its inventory levels quarterly and writes down inventory that has become obsolete or has a cost basis in excess of its expected net realizable value or inventory quantities in excess of expected requirements. Excess requirements are determined based on comparison of existing inventories to forecasted sales, with consideration given to inventory shelf life. Expired inventory is disposed of and the related costs are recognized in cost of goods sold. |
Property, Plant and Equipment, Policy [Policy Text Block] | (h) Property and Equipment, Net Property and equipment, net, are carried at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets, as described in the table below. Maintenance and repairs are expensed as incurred. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is reflected in the accompanying consolidated statements of operations. Asset Estimated useful lives (in years) Computer equipment and software 3 Laboratory and manufacturing equipment 3 Furniture and fixtures 3 Leasehold improvements 5 years or lease term, if shorter |
Lessee, Leases [Policy Text Block] | (i) Right-of-Use Assets Operating lease right-of-use asset and liabilities 12 The Company's lease liabilities are recognized at the applicable lease commencement date based on the present value of the lease payments required to be paid over the lease term. Variable lease payments are expensed as incurred and are not The Company's ROU assets are also recognized at the applicable lease commencement date. The ROU asset equals the carrying amount of the related lease liability, adjusted for any lease payments made prior to lease commencement and lease incentives provided by the lessor, if any. The Company reduces a ROU asset, and the periodic reduction is the difference between the straight-line total lease cost for the period (including reduction of initial direct costs) and the periodic accretion of the lease liability using the effective interest method. The Company's lease terms may The Company's lease contracts often include lease and non-lease components. The Company has elected the practical expedient offered by the standard to not The Company has elected not twelve |
Property, Plant and Equipment, Impairment [Policy Text Block] | (j) Long-lived Assets Impairment assessment of long-lived assets may not December 31, 2020, no |
Clinical Trial Accruals, Policy [Policy Text Block] | (k) Clinical Trial Accruals As part of the process of preparing its consolidated financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiation and may not not may may |
Derivatives, Policy [Policy Text Block] | (l) Derivatives The Company accounts for its derivative instruments as either assets or liabilities on the consolidated balance sheets and measures them at fair value. Derivatives are adjusted to fair value through other (expense) income, net, in the consolidated statements of operations. Derivatives settled in cash or with another financial instrument are reflected in the consolidated statements of cash flows in the same section as the related items. |
Revenue [Policy Text Block] | (m) Revenue Recognition Net product revenue Collaboration agreement revenue In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may not The Company applies judgment in determining whether a combined performance obligation is satisfied at a point in time or over time, and, if over time, concluding upon the appropriate method of measuring progress to be applied for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, as estimates related to the measure of progress change, related revenue recognition is adjusted accordingly. Changes in the Company's estimated measure of progress are accounted for prospectively as a change in accounting estimate. The Company recognizes collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. The Company will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company's consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve may not one December 31, 2020, $683,000, $183,000 $500,000, July 2021. Multiple contracts with the same customer - two one one Contract costs - one not Contract modifications - one not not not |
Shipping and Handling, Policy [Policy Text Block] | (n) Shipping Costs Costs incurred for the shipping of products to customers totaled approximately $0 $6,000 December 31, 2020 2019, |
Standard Product Warranty, Policy [Policy Text Block] | (o) Product Warranties The Company provides a standard warranty of serviceability on all its products for the duration of the product's shelf life, which is two not December 31, 2020 2019. |
Research and Development Expense, Policy [Policy Text Block] | (p) Research and Development The Company's research and development costs are expensed as incurred. Research and development expense include the costs of basic research activities as well as other research, engineering, and technical effort required to develop new products or services or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses and support costs for collaborative partnering programs wherein the Company provides biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. The Company's research and development costs consist primarily of: • Salaries, benefits and other personnel-related expenses, including share-based compensation; • Fees paid for services provided by clinical research organizations, research institutions, consultants and other outside service providers; • Costs to acquire and manufacture materials used in research and development activities and clinical trials; • Laboratory consumables and supplies; • Facility-related expenses allocated to research and development activities; • Fees to collaborators to license technology; and • Depreciation expense for equipment used for research and development and clinical purposes. |
Cost of Goods and Service [Policy Text Block] | (q) Cost of Goods Sold Cost of goods sold includes the costs of raw materials and components, manufacturing personnel and facility costs and other indirect and overhead costs associated with manufacturing the commercial enabling and delivery products, which generate net product revenue. |
Compensation Related Costs, Policy [Policy Text Block] | (r) Share-Based Compensation The Company measures and recognizes share-based compensation expense for equity awards to employees, directors and consultants based on fair value at the grant date. The Company uses the Black-Scholes-Merton (BSM) option pricing model to calculate fair value of its stock option grants. The compensation cost for restricted stock awards is based on the closing price of the Company's common stock on the date of grant. Share-based compensation expense recognized in the consolidated statements of operations is based on the period the services are performed and recognized as compensation expense on a straight-line basis over the requisite service period. The Company accounts for forfeitures as they occur. Measurement of nonemployee awards - The measurement of equity-classified nonemployee awards is fixed at the grant date, and the Company may 505 50 The BSM option pricing model requires the input of subjective assumptions, including the risk-free interest rate, the expected volatility in the value of the Company's common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management's judgment. If factors change and different assumptions are used, the share-based compensation expense could be materially different in the future. These assumptions are estimated as follows: Risk-free Interest Rate The risk-free interest rate assumption is based on the zero Expected Volatility The Company has limited historical data of its own to utilize in determining expected volatility. As such the Company based the volatility assumption on a combined weighted average of the Company's own historical data and that of a selected peer group. The peer group was developed based on companies in the biotechnology and medical device industries whose shares are publicly traded. Expected Term The expected term represents the period of time that options are expected to be outstanding. As the Company does not |
Income Tax, Policy [Policy Text Block] | (s) Income Taxes The Company accounts for income taxes based on the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets, liabilities, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not not In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, forecasts of future taxable income, and ongoing tax planning. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not The Company recognizes and measures benefits for uncertain tax positions using a two first not not second 50% No |
Fair Value of Financial Instruments, Policy [Policy Text Block] | (t) Fair Value of Financial Instruments The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the consolidated financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Where observable prices or inputs are not The Company's financial assets and liabilities consist principally of cash and cash equivalents, accounts receivable, and accounts payable. The fair value of the Company's cash equivalents is determined based on quoted prices in active markets for identical assets. Cash in the Company's operating bank accounts represents the difference between cash in the money market accounts and total cash and cash equivalents reported on the consolidated balance sheets. The recorded values of the Company's accounts receivable and accounts payable approximate their current fair values due to the relatively short-term nature of these accounts. |
Earnings Per Share, Policy [Policy Text Block] | (u) Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Common stock equivalents are comprised of restricted stock units, warrants to purchase common stock and options outstanding under the stock option plans. For all periods presented, there is no |
New Accounting Pronouncements, Policy [Policy Text Block] | (v) Recent Accounting Pronouncements In October 2020, 2020 10— Codification Improvements. December 15, 2020. not not 2020 10. 50 not In March 2020, accelerated filer large accelerated filer No. 34 88365 12b 2 1934 $700 $100 $75 not In December 2019, 2019 12 (Topic 740 December 15, 2020, not In June 2016, No. 2016 13, (Topic 326 December 15, 2022, not Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did not not |
Note 2 - Significant Accounti_2
Note 2 - Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Property, Plant and Equipment, Useful Life [Table Text Block] | Asset Estimated useful lives (in years) Computer equipment and software 3 Laboratory and manufacturing equipment 3 Furniture and fixtures 3 Leasehold improvements 5 years or lease term, if shorter |
Note 3 - Fair Value Measureme_2
Note 3 - Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | As of December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 20,662 $ - $ - $ 20,662 Cash in checking accounts - - - 745 Total cash and cash equivalents $ 20,662 $ — $ — $ 21,407 As of December 31, 2019 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 4,637 $ - $ - $ 4,637 Cash in checking accounts - - - 948 Total cash and cash equivalents $ 4,637 $ — $ — $ 5,585 |
Note 4 - Inventories (Tables)
Note 4 - Inventories (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | December 31, 2020 2019 Raw materials $ — $ — Work in process — — Finished goods — 4 Total $ — $ 4 |
Note 5 - Property and Equipme_2
Note 5 - Property and Equipment, Net (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | December 31, 2020 2019 Computer equipment and software $ 159 $ 132 Laboratory and manufacturing equipment 550 550 Furniture and fixtures 59 55 Leasehold improvements 332 332 Construction in progress 70 69 Property and equipment, gross 1,170 1,138 Less accumulated depreciation (1,025 ) (957 ) Property and equipment, net $ 145 $ 181 |
Note 6 - Operating Lease Righ_2
Note 6 - Operating Lease Right-of-use Asset, Net (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Lease, Cost [Table Text Block] | December 31, 2020 2019 Straight-line rent expense recognized for operating lease $ 601 $ 601 Variable rent expense recognized for operating lease 395 264 Total rent expense $ 996 $ 865 Weighted average remaining lease term (in years) 1.0 2.0 Weighted average discount rate 12.05 % 12.05 % |
Schedule of Operating Leases Cash Flow Information [Table Text Block] | December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities $ 630 $ 612 Cash lease expense (imputed interest expense component of net income) $ 103 $ 161 |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | For the years ending December 31, 2021 $ 649 2022 — 2023 — Thereafter — Total undiscounted lease payments 649 Less imputed interest 35 Total operating lease liabilities $ 614 |
Note 8 - Accrued Expenses and_2
Note 8 - Accrued Expenses and Other Current Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block] | December 31, 2020 2019 Accrued expenses $ 87 $ 10 Accrued salaries and employee benefits 961 652 Accrued director compensation — 648 Accrued clinical trial costs 452 519 Grant liability 615 630 Customer deposits 90 102 Total $ 2,205 $ 2,561 |
Note 10 - Stockholders' Equity
Note 10 - Stockholders' Equity (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Number of Weighted Common Stock Average Warrants Exercise Price Balance, December 31, 2019 2,435,807 $ 6.36 Warrants for common stock sold — — Warrants for common stock exercised (11,083 ) 6.60 Balance, December 31, 2020 2,424,724 $ 6.36 |
Note 11 - Share-based Compens_2
Note 11 - Share-based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Schedule of Share-based Compensation, Expense [Table Text Block] | Years ended December 31, 2020 2019 Cost of goods sold $ - $ 191 Research and development 1,369 1,115 Selling, general and administrative 1,583 1,416 Total stock-based compensation $ 2,952 $ 2,722 |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Options outstanding Number of shares Weighted average exercise price Weighted average remaining contractual term (years) Aggregate intrinsic value (in thousands) Balance, December 31, 2019 821,464 $ 18.99 7.6 $ - Stock options granted 342,232 3.10 Stock options exercised — — Stock options cancelled (49,390 ) 12.79 Balance, December 31, 2020 1,114,306 $ 5.89 7.5 $ 177.1 Options exercisable December 31, 2020 615,470 $ 7.51 6.3 $ 15.6 Options vested and expected to vest 1,114,306 $ 5.89 7.5 $ 177.1 |
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] | Weighted average grant date Number of fair values shares per share Balance, December 31, 2019 36,981 $ 10.56 RSUs granted 381,094 3.93 RSUs vested and settled (137,603 ) 5.48 RSUs forfeited (56,161 ) 3.75 Balance, December 31, 2020 224,311 $ 4.12 |
Share-based Payment Arrangement, Option [Member] | |
Notes Tables | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Years ended December 31, 2020 2019 Risk-free interest rate 0.4 - 1.6% 1.40 - 2.14% Volatility 107 - 112% 74 - 94% Dividend yield None None Expected term (in years) 6.25 - 10.0 6.25 - 10.0 |
Note 13 - Net Loss Per Share (T
Note 13 - Net Loss Per Share (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Years ended December 31, 2020 2019 Numerator: Net loss $ (15,004 ) $ (14,709 ) Denominator: Weighted average shares used to compute net loss per share, basic and diluted 10,118,682 5,644,328 Net loss per share, basic and diluted $ (1.48 ) $ (2.61 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | At December 31, 2020 2019 Stock options to purchase common stock 1,114,306 821,464 Unvested restricted stock units 8,200 36,981 Common stock warrants 2,424,724 2,435,808 Total 3,547,230 3,294,253 |
Note 14 - Income Taxes (Tables)
Note 14 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Years ended December 31, 2020 2019 Tax at federal statutory rate $ (3,151 ) $ (3,089 ) State, net of federal benefit (449 ) (414 ) Research and development credit (276 ) (225 ) Share-based compensation 649 446 PPP Note forgiveness (107 ) - Other 2 5 Change in valuation allowance 3,332 3,277 Total provision for income taxes $ — $ - |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | Years ended December 31, 2020 2019 Accrued compensation $ 225 $ 148 Inventory adjustments 335 297 Depreciation and amortization 90 98 Share-based compensation 686 744 Net operating loss and tax credit carryforwards 26,931 23,809 Other 173 11 Gross Deferred Tax Asset 28,440 25,107 Valuation Allowance (28,440 ) (25,107 ) Net deferred tax asset $ - $ - |
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] | Years ended December 31, 2020 2019 Balance, beginning of year $ 1,046 $ 891 Additions based on tax positions related to the current year 189 155 Balance, end of year $ 1,235 $ 1,046 |
Note 2 - Significant Accounti_3
Note 2 - Significant Accounting Policies 1 (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Retained Earnings (Accumulated Deficit), Ending Balance | $ (116,074,000) | $ (101,070,000) |
Cash and Cash Equivalents, at Carrying Value, Ending Balance | 21,407,000 | 5,585,000 |
Accounts Receivable, Allowance for Credit Loss, Current | 16,000 | 2,000 |
Impairment of Long-Lived Assets Held-for-use | 0 | |
Cost of Goods and Services Sold, Total | $ 4,000 | 358,000 |
Standard Product Warranty, Term (Year) | 2 years | |
Standard Product Warranty Accrual, Ending Balance | $ 0 | 0 |
Shipping and Handling [Member] | ||
Cost of Goods and Services Sold, Total | $ 0 | $ 6,000 |
Note 2 - Significant Accounti_4
Note 2 - Significant Accounting Policies 2 (Details Textual) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | Dec. 31, 2020USD ($) |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Month) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 683,000 |
Service [Member] | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Month) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 183,000 |
License [Member] | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Month) | 1 year |
Revenue, Remaining Performance Obligation, Amount | $ 500,000 |
Note 2 - Significant Accounti_5
Note 2 - Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details) | 12 Months Ended |
Dec. 31, 2020 | |
Computer Equipment and Software [Member] | |
Estimated useful lives (Year) | 3 years |
Laboratory and Manufacturing Equipment [Member] | |
Estimated useful lives (Year) | 3 years |
Furniture and Fixtures [Member] | |
Estimated useful lives (Year) | 3 years |
Leasehold Improvements [Member] | |
Estimated useful lives | 5 years or lease term, if shorter |
Note 3 - Fair Value Measureme_3
Note 3 - Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Cash and Cash Equivalents, Fair Value | $ 21,407 | $ 5,585 |
Money Market Funds [Member] | ||
Cash and Cash Equivalents, Fair Value | 20,662 | 4,637 |
Demand Deposits [Member] | ||
Cash and Cash Equivalents, Fair Value | 745 | 948 |
Fair Value, Inputs, Level 1 [Member] | ||
Cash and Cash Equivalents, Fair Value | 20,662 | 4,637 |
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member] | ||
Cash and Cash Equivalents, Fair Value | 20,662 | 4,637 |
Fair Value, Inputs, Level 1 [Member] | Demand Deposits [Member] | ||
Cash and Cash Equivalents, Fair Value | ||
Fair Value, Inputs, Level 2 [Member] | ||
Cash and Cash Equivalents, Fair Value | ||
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member] | ||
Cash and Cash Equivalents, Fair Value | ||
Fair Value, Inputs, Level 2 [Member] | Demand Deposits [Member] | ||
Cash and Cash Equivalents, Fair Value | ||
Fair Value, Inputs, Level 3 [Member] | ||
Cash and Cash Equivalents, Fair Value | ||
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member] | ||
Cash and Cash Equivalents, Fair Value | ||
Fair Value, Inputs, Level 3 [Member] | Demand Deposits [Member] | ||
Cash and Cash Equivalents, Fair Value |
Note 4 - Inventories (Details T
Note 4 - Inventories (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Cost of Goods Sold [Member] | ||
Inventory Write-down | $ 2,000 | $ 36,000 |
Note 4 - Inventories - Summary
Note 4 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Raw materials | ||
Work in process | ||
Finished goods | 4 | |
Total | $ 4 |
Note 5 - Property and Equipme_3
Note 5 - Property and Equipment, Net (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Depreciation, Total | $ 68,000 | $ 111,000 |
Note 5 - Property and Equipme_4
Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Property and equipment, gross | $ 1,170 | $ 1,138 |
Less accumulated depreciation | (1,025) | (957) |
Property and equipment, net | 145 | 181 |
Computer Equipment and Software [Member] | ||
Property and equipment, gross | 159 | 132 |
Laboratory and Manufacturing Equipment [Member] | ||
Property and equipment, gross | 550 | 550 |
Furniture and Fixtures [Member] | ||
Property and equipment, gross | 59 | 55 |
Leasehold Improvements [Member] | ||
Property and equipment, gross | 332 | 332 |
Construction in Progress [Member] | ||
Property and equipment, gross | $ 70 | $ 69 |
Note 6 - Operating Lease Righ_3
Note 6 - Operating Lease Right-of-use Asset, Net - Impact of New Lease Standard (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Straight-line rent expense recognized for operating lease | $ 601 | $ 601 |
Variable rent expense recognized for operating lease | 395 | 264 |
Total rent expense | $ 996 | $ 865 |
Weighted average remaining lease term (in years) (Year) | 1 year | 2 years |
Weighted average discount rate | 12.05% | 12.05% |
Note 6 - Operating Lease Righ_4
Note 6 - Operating Lease Right-of-use Asset, Net - Supplement Cash Flow Information (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Cash paid for amounts included in the measurement of lease liabilities | $ 630 | $ 612 |
Cash lease expense (imputed interest expense component of net income) | $ 103 | $ 161 |
Note 6 - Operating Lease Righ_5
Note 6 - Operating Lease Right-of-use Asset, Net - Future Minimum Lease Payments Under Operating Lease (Details) $ in Thousands | Dec. 31, 2020USD ($) |
2021 | $ 649 |
2022 | |
2023 | |
Thereafter | |
Total undiscounted lease payments | 649 |
Less imputed interest | 35 |
Total operating lease liabilities | $ 614 |
Note 8 - Accrued Expenses and_3
Note 8 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Accrued expenses | $ 87 | $ 10 |
Accrued salaries and employee benefits | 961 | 652 |
Accrued director compensation | 648 | |
Accrued clinical trial costs | 452 | 519 |
Grant liability | 615 | 630 |
Customer deposits | 90 | 102 |
Total | $ 2,205 | $ 2,561 |
Note 9 - Note Payable Under P_2
Note 9 - Note Payable Under Paycheck Protection Program (Details Textual) - Paycheck Protection Program CARES Act [Member] - USD ($) | Nov. 02, 2020 | May 01, 2020 | Dec. 31, 2020 | Dec. 31, 2019 |
Proceeds from Issuance of Long-term Debt, Total | $ 506,413 | |||
Debt Instrument, Principle Amount Forgiven | $ 506,000 | |||
Debt Instrument, Interest Amount Forgiven | $ 3,000 | |||
Gain (Loss) on Extinguishment of Debt, Total | $ 509,000 |
Note 10 - Stockholders' Equit_2
Note 10 - Stockholders' Equity (Details Textual) | Dec. 24, 2020shares | Dec. 18, 2020USD ($)$ / sharesshares | Dec. 16, 2020USD ($)$ / sharesshares | Jun. 19, 2020USD ($)$ / sharesshares | Jun. 17, 2020shares | Jun. 08, 2020USD ($)shares | Sep. 04, 2019USD ($)shares | Aug. 06, 2019USD ($)$ / sharesshares | Jul. 05, 2019USD ($)shares | Jun. 06, 2019 | Dec. 24, 2018USD ($)$ / sharesshares | Dec. 31, 2020USD ($)$ / sharesshares | Dec. 31, 2019USD ($)$ / sharesshares | Aug. 05, 2019$ / shares |
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | ||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 9,196,000 | |||||||||||||
Stock Issued During Period, Value, Issued for Services | $ | $ 148,000 | |||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 6.75 | $ 6.36 | $ 6.36 | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 296,296 | |||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | ||||||||||||||
Common Stock, Shares, Issued, Total (in shares) | 592,592 | 16,297,381 | 6,825,183 | |||||||||||
Sale of Stock, Price Per Share (in dollars per share) | $ / shares | $ 6.75 | |||||||||||||
Proceeds from Issuance of Common Stock and Warrants | $ | $ 3,800,000 | $ 10,452,000 | ||||||||||||
Payments of Stock Issuance Costs | $ | $ 200,000 | $ 2,635,000 | ||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 11,083 | 11,083 | ||||||||||||
Stock Issued During Period, Shares, Warrants Exercises (in shares) | 470 | |||||||||||||
Reverse Stock Split [Member] | ||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 9 | |||||||||||||
Conversion of Convertible Notes to Units [Member] | ||||||||||||||
Debt Conversion, Original Debt, Amount | $ | $ 633,000 | $ 52,000 | ||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 210,887 | 521,000 | ||||||||||||
Interest Expense, Debt, Total | $ | 112,000 | |||||||||||||
Amortization of Debt Discount (Premium) | $ | 104,000 | |||||||||||||
Convertible Promissory Note [Member] | ||||||||||||||
Proceeds from Convertible Debt | $ | $ 625,000 | |||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 14.00% | |||||||||||||
Debt Conversion, Original Debt, Discount of Securities Offered | 50.00% | |||||||||||||
Warrants Issued to Underwriters [Member] | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 6.60 | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 11,958 | |||||||||||||
Two Former Board Members [Member] | ||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 29,625 | |||||||||||||
Stock Issued During Period, Value, Issued for Services | $ | $ 148,000 | |||||||||||||
Underwriters [Member] | ||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 75,000 | |||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 420,000 | |||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 250,000 | |||||||||||||
Underwriting Discounts and Commissions | $ | $ 32,000 | |||||||||||||
The $10.5 Million Registered Direct Offering [Member] | ||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 2,038,836 | |||||||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | |||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 5.15 | |||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 10,500,000 | $ 9,765,000 | ||||||||||||
Placement Agent Fee | 7.00% | |||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 9,800,000 | 10,500,000 | ||||||||||||
The $8.5 Million Registered Direct Offering [Member] | ||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,789,474 | |||||||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | |||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 4.75 | |||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 8,500,000 | 7,827,000 | ||||||||||||
Placement Agent Fee | 7.00% | |||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 7,800,000 | 8,500,000 | ||||||||||||
Placement Agent Maximum Expenses Reimbursement Amount | $ | $ 40,000 | |||||||||||||
Public Offering [Member] | ||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 4,762,000 | |||||||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | ||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 2.10 | |||||||||||||
Stock Issued During Period, Value, New Issues | $ | 10,273,000 | |||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 10,300,000 | $ 11,500,000 | ||||||||||||
Underwriters, Additional Common Shares Authorized to Purchase (in shares) | 714,190 | 250,000 | ||||||||||||
Number of Units Offered to Sale (in shares) | 1,666,667 | |||||||||||||
Number of Common Stock in Each Unit (in shares) | 1 | |||||||||||||
Number of Common Stock Called by Each Unit (in shares) | 1 | |||||||||||||
Unit Offering Price (in dollars per share) | $ / shares | $ 6 | |||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 6.30 | |||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||
Underwriters, Additional Warrants Authorized to Purchase (in shares) | 250,000 | |||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 8,800,000 | |||||||||||||
Private Placement Unit [Member] | ||||||||||||||
Number of Common Stock in Each Unit (in shares) | 1 | |||||||||||||
Number of Common Stock Called by Each Unit (in shares) | 1 | |||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 3 | $ 8 |
Note 10 - Stockholders' Equit_3
Note 10 - Stockholders' Equity - Warrants (Details) - $ / shares | Dec. 24, 2020 | Dec. 31, 2020 |
Balance, beginning (in shares) | 2,435,807 | |
Balance, beginning, weighted average exercise price (in dollars per share) | $ 6.36 | |
Warrants for common stock sold (in shares) | ||
Warrants for common stock sold, weighted average exercise price (in dollars per share) | ||
Warrants for common stock exercised (in shares) | (11,083) | (11,083) |
Warrants for common stock exercised, weighted average exercise price (in dollars per share) | $ 6.60 | |
Balance, ending (in shares) | 2,424,724 | |
Balance, ending, weighted average exercise price (in dollars per share) | $ 6.36 |
Note 11 - Share-based Compens_3
Note 11 - Share-based Compensation (Details Textual) - USD ($) | Jan. 01, 2021 | Jan. 29, 2020 | Dec. 31, 2020 | Dec. 31, 2019 |
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 5.32 | $ 3.10 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 515,036 | 342,232 | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount, Total | $ 569,000 | |||
Share-based Payment Arrangement, Expense | 412,000 | $ 2,952,000 | $ 2,722,000 | |
Share-based Payment Arrangement, Amount Capitalized | $ 157,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Remaining Weighted Average Award Vesting Period (Year) | 3 years | |||
Share Price (in dollars per share) | $ 3.46 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 0 | $ 0 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 1.73 | $ 3.87 | ||
Employees [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 342,232 | 254,785 | ||
Non-employee Directors and Employees [Member] | ||||
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | $ 2,100,000 | |||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 73 days | |||
Minimum [Member] | ||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 10.05 | |||
Maximum [Member] | ||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 97.21 | |||
The 2016 Plan [Member] | ||||
Annual Increase, Percentage of Common Shares Outstanding | 4.00% | |||
Annual Increase, Number of Common Shares (in shares) | 268,997 | |||
The 2016 Plan [Member] | Subsequent Event [Member] | ||||
Annual Increase, Number of Common Shares (in shares) | 1,000,000 | |||
Share-based Payment Arrangement, Option [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 4 years | |||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | |||
Share-based Payment Arrangement, Option [Member] | The 2016 Plan [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 160,020 | |||
Restricted Stock Units (RSUs) [Member] | ||||
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | $ 37,000 | |||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 109 days | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 381,094 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) | 224,311 | 36,981 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Not Settled, Number, Ending Balance (in shares) | 216,111 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Not Yet Vested, Number, Ending Balance (in shares) | 8,200 | |||
Restricted Stock Units (RSUs) [Member] | Management [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 113,976 | 34,713 | ||
Restricted Stock Units (RSUs) [Member] | Director [Member] | ||||
Number of Share-based Awards Granted Quarterly, Numerator in Ratio | $ 92,500 | |||
Number of Share-based Awards Granted Quarterly, Denominator in Ratio | 4 | |||
Restricted Stock Units (RSUs) [Member] | Director [Member] | Share-based Payment Arrangement, Tranche One [Member] | ||||
Share-based Payment Arrangement, Expense | $ 190,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 122,977 | |||
Restricted Stock Units (RSUs) [Member] | Director [Member] | Share-based Payment Arrangement, Tranche Two [Member] | ||||
Share-based Payment Arrangement, Expense | $ 613,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 69,321 | |||
Restricted Stock Units (RSUs) [Member] | Maximum [Member] | Director [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 2 years |
Note 11 - Share-based Compens_4
Note 11 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) | Jan. 29, 2020 | Dec. 31, 2020 | Dec. 31, 2019 |
Share-based compensation expense | $ 412,000 | $ 2,952,000 | $ 2,722,000 |
Cost of Goods Sold [Member] | |||
Share-based compensation expense | 191,000 | ||
Research and Development Expense [Member] | |||
Share-based compensation expense | 1,369,000 | 1,115,000 | |
Selling, General and Administrative Expenses [Member] | |||
Share-based compensation expense | $ 1,583,000 | $ 1,416,000 |
Note 11 - Share-based Compens_5
Note 11 - Share-based Compensation - Stock Option Activity (Details) - USD ($) | Jan. 29, 2020 | Dec. 31, 2020 | Dec. 31, 2019 |
Stock options outstanding, beginning of period (in shares) | 821,464 | ||
Balance, weighted average exercise price, beginning of period (in dollars per share) | $ 18.99 | ||
Stock options outstanding, weighted average remaining contractual term (Year) | 7 years 182 days | 7 years 219 days | |
Stock options outstanding, aggregate intrinsic value | $ 177,100 | ||
Stock options granted (in shares) | 515,036 | 342,232 | |
Stock options granted, weighted average exercise price (in dollars per share) | $ 5.32 | $ 3.10 | |
Stock options exercised (in shares) | |||
Stock options exercised, weighted average exercise price (in dollars per share) | |||
Stock options cancelled (in shares) | (49,390) | ||
Stock options canceled, weighted average exercise price (in dollars per share) | $ 12.79 | ||
Stock options outstanding, end of period (in shares) | 1,114,306 | 821,464 | |
Balance, weighted average exercise price, end of period (in dollars per share) | $ 5.89 | $ 18.99 | |
Options exercisable (in shares) | 615,470 | ||
Options exercisable, weighted average exercise price (in dollars per share) | $ 7.51 | ||
Options exercisable, weighted average remaining contractual term (Year) | 6 years 109 days | ||
Options exercisable, aggregate intrinsic value | $ 15,600 | ||
Options vested and expected to vest (in shares) | 1,114,306 | ||
Options vested and expected to vest, weighted average exercise price (in dollars per share) | $ 5.89 | ||
Options vested and expected to vest, weighted average remaining contractual term (Year) | 7 years 182 days | ||
Options vested and expected to vest, aggregate intrinsic value | $ 177,100 |
Note 11 - Share-based Compens_6
Note 11 - Share-based Compensation - Valuation Assumptions for Employee Stock Options (Details) - Share-based Payment Arrangement, Option [Member] | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Dividend yield | 0.00% | 0.00% |
Minimum [Member] | ||
Risk-free interest rate | 0.40% | 1.40% |
Volatility | 107.00% | 74.00% |
Expected term (Year) | 6 years 91 days | 6 years 91 days |
Maximum [Member] | ||
Risk-free interest rate | 1.60% | 2.14% |
Volatility | 112.00% | 94.00% |
Expected term (Year) | 10 years | 10 years |
Note 11 - Share-based Compens_7
Note 11 - Share-based Compensation - Summary of Non-vested RSUs (Details) - Restricted Stock Units (RSUs) [Member] | 12 Months Ended |
Dec. 31, 2020$ / sharesshares | |
Balance, shares (in shares) | shares | 36,981 |
Balance, weighted average grant date fair value per share (in dollars per share) | $ / shares | $ 10.56 |
RSUs granted, shares (in shares) | shares | 381,094 |
RSUs granted, weighted average grant date fair value per share (in dollars per share) | $ / shares | $ 3.93 |
RSUs vested and settled (in shares) | shares | (137,603) |
RSUs vested and settled, weighted average grant date fair value per share (in dollars per share) | $ / shares | $ 5.48 |
RSUs forfeited (in shares) | shares | (56,161) |
RSUs forfeited, weighted average grant date fair value per share (in dollars per share) | $ / shares | $ 3.75 |
Balance, shares (in shares) | shares | 224,311 |
Balance, weighted average grant date fair value per share (in dollars per share) | $ / shares | $ 4.12 |
Note 12 - Concentrations (Detai
Note 12 - Concentrations (Details Textual) - Customer Concentration Risk [Member] | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Revenue Benchmark [Member] | Customer One [Member] | ||
Concentration Risk, Percentage | 70.00% | 43.00% |
Revenue Benchmark [Member] | Customer Two [Member] | ||
Concentration Risk, Percentage | 16.00% | 25.00% |
Accounts Receivable [Member] | ||
Concentration Risk, Percentage | 15.00% | |
Accounts Receivable [Member] | Customer One [Member] | ||
Concentration Risk, Percentage | 22.00% | |
Accounts Receivable [Member] | Customer Two [Member] | ||
Concentration Risk, Percentage | 18.00% | |
Accounts Receivable [Member] | Customer Three [Member] | ||
Concentration Risk, Percentage | 11.00% |
Note 13 - Net Loss Per Share -
Note 13 - Net Loss Per Share - Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Net loss | $ (15,004) | $ (14,709) |
Weighted-average shares used in computing net loss per share, basic and diluted (in shares) | 10,118,682 | 5,644,328 |
Net loss per share, basic and diluted (in dollars per share) | $ (1.48) | $ (2.61) |
Note 13 - Net Loss Per Share _2
Note 13 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Antidilutive securities (in shares) | 3,547,230 | 3,294,253 |
Share-based Payment Arrangement, Option [Member] | ||
Antidilutive securities (in shares) | 1,114,306 | 821,464 |
Restricted Stock Units (RSUs) [Member] | ||
Antidilutive securities (in shares) | 8,200 | 36,981 |
Warrant [Member] | ||
Antidilutive securities (in shares) | 2,424,724 | 2,435,808 |
Note 14 - Income Taxes (Details
Note 14 - Income Taxes (Details Textual) - USD ($) | Nov. 02, 2020 | May 01, 2020 | Dec. 31, 2020 | Dec. 31, 2019 |
Income Tax Expense (Benefit), Total | $ 0 | $ 0 | ||
Deferred Tax Liabilities, Net, Total | 0 | 0 | ||
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | 3,300,000 | 3,200,000 | ||
Unrecognized Tax Benefits that Would Impact Effective Tax Rate | 895,000 | $ 753,000 | ||
Paycheck Protection Program CARES Act [Member] | ||||
Proceeds from Issuance of Long-term Debt, Total | $ 506,413 | |||
Forgiveness of Notes Payable | $ 506,413 | |||
Interest Payable, Forgiven During Period | $ 3,000 | |||
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | ||||
Operating Loss Carryforwards, Total | 91,500,000 | |||
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | ||||
Tax Credit Carryforward, Amount | 2,800,000 | |||
State and Local Jurisdiction [Member] | ||||
Operating Loss Carryforwards, Total | 62,700,000 | |||
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member] | ||||
Tax Credit Carryforward, Amount | $ 2,100,000 |
Note 14 - Income Taxes - Effect
Note 14 - Income Taxes - Effective Income Tax Reconciliation (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Tax at federal statutory rate | $ (3,151,000) | $ (3,089,000) |
State, net of federal benefit | (449,000) | (414,000) |
Research and development credit | (276,000) | (225,000) |
Share-based compensation | 649,000 | 446,000 |
PPP Note forgiveness | (107,000) | |
Other | 2,000 | 5,000 |
Change in valuation allowance | 3,332,000 | 3,277,000 |
Total provision for income taxes | $ 0 | $ 0 |
Note 14 - Income Taxes - Compon
Note 14 - Income Taxes - Components of the Net Deferred Income Tax Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Accrued compensation | $ 225 | $ 148 |
Inventory adjustments | 335 | 297 |
Depreciation and amortization | 90 | 98 |
Share-based compensation | 686 | 744 |
Net operating loss and tax credit carryforwards | 26,931 | 23,809 |
Other | 173 | 11 |
Gross Deferred Tax Asset | 28,440 | 25,107 |
Valuation Allowance | (28,440) | (25,107) |
Net deferred tax asset |
Note 14 - Income Taxes - Aggreg
Note 14 - Income Taxes - Aggregate Changes in the Balance of Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Balance, beginning of year | $ 1,046 | $ 891 |
Additions based on tax positions related to the current year | 189 | 155 |
Balance, end of year | $ 1,235 | $ 1,046 |
Note 16 - Grant Funding (Detail
Note 16 - Grant Funding (Details Textual) - Grant Agreement [Member] - TEDCO [Member] - USD ($) | 1 Months Ended | 12 Months Ended |
Jun. 30, 2016 | Dec. 31, 2020 | |
Grant Funding Available | $ 750,000 | |
Grant Funding, Term of Grant (Year) | 3 years | |
Proceeds from Grant Funding | $ 750,000 | |
Research and Development Expense Reduction from Qualified Grant Funding | 135,000 | |
Deferred Revenue from Grants, Current | $ 615,000 |
Note 17 - Related Party Trans_2
Note 17 - Related Party Transactions (Details Textual) - USD ($) | Jan. 29, 2020 | Jul. 05, 2019 | Aug. 31, 2016 | Dec. 31, 2020 | Dec. 31, 2019 | Aug. 19, 2016 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 515,036 | 342,232 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 5.89 | $ 18.99 | ||||
Share-based Payment Arrangement, Noncash Expense, Total | $ 2,952,000 | $ 2,722,000 | ||||
Convertible Promissory Note [Member] | ||||||
Proceeds from Convertible Debt | $ 625,000 | |||||
BSLF, L.L.C. [Member] | Funding Agreement [Member] | ||||||
Percentage of Remaining Litigation Proceeds Up to Three Times the Actual Funding Amount | 50.00% | |||||
Percentage of Remaining Litigation Proceeds | 30.00% | |||||
Agreement Termination Period (Day) | 10 days | |||||
Due from Related Parties, Total | $ 618,000 | |||||
Chairman and Chief Executive Officer of OPKO [Member] | ||||||
Related Party, Ownership Percentage | 5.00% | |||||
OPKO [Member] | Consulting Services [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 46,553 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 4 years | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 16.20 | |||||
Consulting Agreement, Term (Year) | 4 years | |||||
Consulting Agreement, Term, Length of Automatic Renewal Periods (Year) | 1 year | |||||
OPKO [Member] | Chairman and Chief Executive Officer of OPKO [Member] | ||||||
Share-based Payment Arrangement, Noncash Expense, Total | 225,000 | |||||
Share-based Payment Arrangement, Options Modifications | $ 167,000 |
Note 18 - Employee Benefit Pl_2
Note 18 - Employee Benefit Plans (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent | 75.00% | |
Defined Contribution Plan, Employer Discretionary Contribution Amount | $ 26,000 | $ 25,000 |
Note 19 - Subsequent Events (De
Note 19 - Subsequent Events (Details Textual) - USD ($) | Mar. 29, 2021 | Feb. 17, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 24, 2018 |
Common Stock, Shares, Issued, Total (in shares) | 16,297,381 | 6,825,183 | 592,592 | ||
Subsequent Event [Member] | Purchase Agreement with Lincoln Park [Member] | |||||
Proceeds from Issuance of Common Stock | $ 2,000,000 | ||||
Common Stock, Shares, Issued, Total (in shares) | 373,832 | ||||
Shares Issued, Price Per Share (in dollars per share) | $ 5.35 | ||||
Sale of Stock, Aggregate Value, Maximum | $ 20,000,000 | ||||
Stock Issuable, Shares, Commitment Fess (in shares) | 75,000 | ||||
Stock Issuable, Additional Shares as a Further Commitment Fee (in shares) | 50,000 | ||||
Stock Issued During the Period, Shares, Commission Fees (in shares) | 80,000 | ||||
Stock Issued During the Period, Shares on a pro Rata Basis in Respect of the Initial Purchase Included in Total Stock Issued as Commitment Shares (in shares) | 5,000 | ||||
Subsequent Event [Member] | Helix Biotherapeutic Delivery System [Member] | |||||
Proceeds From Agreement | $ 500,000 |